170 related articles for article (PubMed ID: 8513845)
21. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.
Sindrup SH; Brøsen K; Hansen MG; Aaes-Jørgensen T; Overø KF; Gram LF
Ther Drug Monit; 1993 Feb; 15(1):11-7. PubMed ID: 8451774
[TBL] [Abstract][Full Text] [Related]
22. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers.
Begré S; von Bardeleben U; Ladewig D; Jaquet-Rochat S; Cosendai-Savary L; Golay KP; Kosel M; Baumann P; Eap CB
J Clin Psychopharmacol; 2002 Apr; 22(2):211-5. PubMed ID: 11910269
[TBL] [Abstract][Full Text] [Related]
23. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
[TBL] [Abstract][Full Text] [Related]
24. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.
Skjelbo E; Brøsen K; Hallas J; Gram LF
Clin Pharmacol Ther; 1991 Jan; 49(1):18-23. PubMed ID: 1988236
[TBL] [Abstract][Full Text] [Related]
25. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
[TBL] [Abstract][Full Text] [Related]
26. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
Laine K; De Bruyn S; Björklund H; Rouru J; Hänninen J; Scheinin H; Anttila M
Eur J Clin Pharmacol; 2004 Feb; 59(12):893-8. PubMed ID: 14730412
[TBL] [Abstract][Full Text] [Related]
27. Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH.
Gross AS; Mikus G; Fischer C; Eichelbaum M
Eur J Clin Pharmacol; 1991; 40(2):155-62. PubMed ID: 1906003
[TBL] [Abstract][Full Text] [Related]
28. The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide.
Mikus G; Gross AS; Beckmann J; Hertrampf R; Gundert-Remy U; Eichelbaum M
Clin Pharmacol Ther; 1989 May; 45(5):562-7. PubMed ID: 2498026
[TBL] [Abstract][Full Text] [Related]
29. Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants.
Puozzo C; Lens S; Reh C; Michaelis K; Rosillon D; Deroubaix X; Deprez D
Clin Pharmacokinet; 2005; 44(9):977-88. PubMed ID: 16122284
[TBL] [Abstract][Full Text] [Related]
30. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
31. Dose adjustment of paroxetine based on CYP2D6 activity score inferred metabolizer status in Chinese Han patients with depressive or anxiety disorders: a prospective study and cross-ethnic meta-analysis.
Liao Y; Sun Y; Guo J; Kang Z; Sun Y; Zhang Y; He J; Huang C; Sun X; Zhang JM; Wang J; Wang HN; Chen ZY; Wang K; Pan J; Ni AH; Weng S; Wang A; Cao C; Sun L; Zhang Y; Kuang L; Zhang Y; Liu Z; Yue W;
EBioMedicine; 2024 Jun; 104():105165. PubMed ID: 38776596
[TBL] [Abstract][Full Text] [Related]
32. Oxidative phenotype polymorphism (P450 2D6) and metabolism of toluene.
Pelclová D; Mráz J; Patzelová V; Pícková J; Pospísil J; Vodicková L; Hornychová M; Vejlupková J
Int J Clin Pharmacol Ther; 1996 Jan; 34(1):38-42. PubMed ID: 8688995
[TBL] [Abstract][Full Text] [Related]
33. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population.
Halling J; Weihe P; Brosen K
Br J Clin Pharmacol; 2008 Jan; 65(1):134-8. PubMed ID: 17764479
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
35. Nonlinear kinetics of imipramine in low and medium plasma level ranges.
Sindrup SH; Brøsen K; Gram LF
Ther Drug Monit; 1990 Sep; 12(5):445-9. PubMed ID: 2293406
[TBL] [Abstract][Full Text] [Related]
36. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults.
Nichols AI; Fatato P; Shenouda M; Paul J; Isler JA; Pedersen RD; Jiang Q; Ahmed S; Patroneva A
J Clin Pharmacol; 2009 Feb; 49(2):219-28. PubMed ID: 19001559
[TBL] [Abstract][Full Text] [Related]
37. Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers.
Prakash C; Cui D; Baxter JG; Bright GM; Miceli J; Wilner K
Drug Metab Dispos; 1998 May; 26(5):448-56. PubMed ID: 9571226
[TBL] [Abstract][Full Text] [Related]
38. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
Dorne JL; Walton K; Slob W; Renwick AG
Food Chem Toxicol; 2002 Nov; 40(11):1633-56. PubMed ID: 12176090
[TBL] [Abstract][Full Text] [Related]
39. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
40. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.
Brøsen K; Davidsen F; Gram LF
Br J Clin Pharmacol; 1990 Feb; 29(2):248-53. PubMed ID: 2306418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]